Table 1.

Details and results of 2 studies in adults with asthma that examined the effect of quadrupling inhaled corticosteroids as part of an asthma action plan: The Oborne et al study cohort was about 54 y of age and 39% male; the McKeever et al study cohort was about 56 y of age and 33% male.

STUDY GROUPOBORNE ET AL,2 2009 (N = 403)MCKEEVER ET AL,3 2018 (N = 1922)
STARTED ORAL CSADVERSE EVENTS IN THOSE WHO STARTED THE INHALER*SEVERE EXACERBATIONSTARTED ORAL CSHOSPITALIZATION FOR ASTHMATHOSE WHO REACHED ZONE 2 OF THEIR SELF-MANAGEMENT PLAN
NONSERIOUS ADVERSE EVENTSORAL CANDIDIASIS OR DYSPHONIA
Placebo or control§14%8% (3 of 38)52%40%1.8%2% (10 of 552)1.6% (9 of 552)
Quadruple dose9%16% (9 of 56)45%33%0.3%7% (41 of 562)6.4% (36 of 562)
  • CS—corticosteroids.

  • * 23% of the cohort.

  • Treatment with oral CS or an unscheduled health care consultation for asthma.

  • 58% of the cohort.

  • § Placebo group in the study by Oborne et al2 and control group in the study by McKeever et al.3

  • Not statistically different; however, in those patients who actually started the study inhaler there was a statistically significant reduction: 50% (19 of 38) versus 21% (12 of 56).

  • No statistical tests reported.